Oral semaglutide approved
The FDA approved oral semaglutide as the first GLP‑1 pill authorized for weight loss, marking a new non‑injectable option tied to the Wegovy brand (ajmc.com). Local clinicians are already assessing how a pill could change access and patient preferences compared with injectable GLP‑1s (wmtw.com).
A gut hormone called glucagon-like peptide-1 acts like a fullness signal after you eat. The Food and Drug Administration has now cleared a pill version of semaglutide, sold as Wegovy, for adults who need prescription weight-loss treatment. (fda.gov) Semaglutide is the same active ingredient used in Wegovy shots, but this version is taken by mouth once a day. The approval letter says the tablets are used with a reduced-calorie diet and more physical activity for adults with obesity, or adults with overweight plus at least one weight-related medical condition. (fda.gov) The agency approved the tablets on December 22, 2025, under New Drug Application 218316. The prescribing information lists a 25 milligram oral daily dose and says the tablets also carry Wegovy’s cardiovascular indication for some adults with established cardiovascular disease and obesity or overweight. (fda.gov) (novo-pi.com) In plain terms, the change is not a new drug class but a new way to take one of the best-known obesity medicines. That matters for patients who delayed treatment because they did not want weekly injections or could not manage them easily. (cnbc.com) (wmtw.com) Early rollout data suggest the pill is drawing in people who had not used branded glucagon-like peptide-1 drugs before. CNBC reported on April 7 that many early patients cited fear of needles or the cost of injections as reasons they waited for a tablet. (cnbc.com) The label also shows the tradeoffs. Wegovy tablets carry the same boxed warning about thyroid C-cell tumors seen in rodents, and the same contraindication for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (novo-pi.com) Clinical testing for the tablet ran 64 weeks in adults with obesity or overweight and at least one weight-related condition. In that study, 204 adults received Wegovy tablets, according to the Food and Drug Administration-approved label. (fda.gov) Doctors are already framing the pill as a preference question as much as a medical one. WMTW reported April 13 that MaineHealth physician Dr. Peter Amann said the tablet has a similar effect to injectable versions, while giving patients another way to start treatment. (wmtw.com) The timing is also tightening competition in obesity drugs. Eli Lilly won Food and Drug Administration approval for its own oral obesity drug, Foundayo, in early April 2026, ending Novo Nordisk’s brief run as the only company with a prescription weight-loss pill in this class. (managedhealthcareexecutive.com) (wmtw.com) For patients, the practical shift is simple: the best-known weight-loss shot now has a tablet form on the market. The next test is whether insurers, doctors, and patients treat that added convenience as enough reason to widen use. (cnbc.com)
